Earnings quality
Compare earnings and operating cash flow for earnings quality.
Hanmi Pharm. Co., Ltd.
Ticker 128940 Β· π°π· Korea Β· Consolidated K-IFRS Β· amounts in won
Filed 2025-03-31 Β· Period end 2024-12-31
Takeaway
Dig deeperThe numbers send mixed signals β dig into cash flow and leverage before drawing a conclusion.
equity ratio is 53.7%.
Mixed signals β use cash flow and the balance sheet before treating the year as clean.
ActionDig deeper
OP marginβ
Equity ratio53.7%
Last priceKRW 372,500
Trailing P/Eβ
Look at next
- Compare operating cash flow to reported profit across the last two years.
- Open English IR for management commentary on outlook and capital allocation.
- Overlay peers on Compare before judging relative momentum.
About the company
Hanmi Pharm. Co., Ltd. is a Korea-listed company with consolidated financial statements filed on DART (Open DART).
Compare trends
Tel 02-410-9114 Β· As of filing date 2024-12-31
Financial statements
Income statement
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Revenue | β©1.5T | β©1.5T |
| Cost of sales* | β | β |
| Gross profit | β | β |
| Operating profit | β | β |
| Finance income | β | β |
| Finance costs | β | β |
| Income tax | β | β |
| Profit for the period | β | β |
| Profit to owners | β | β |
| Basic EPS | β | β |
Balance sheet
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Cash & equivalents | β©55.0B | β©192.3B |
| Current assets | β©730.6B | β©746.3B |
| Non-current assets | β©1.2T | β©1.3T |
| Total assets | β©1.9T | β©2.0T |
| Current liabilities | β©704.8B | β©682.8B |
| Short-term borrowings | β©336.1B | β©370.6B |
| Non-current liabilities* | β©93.7B | β©97.3B |
| Total liabilities | β©798.5B | β©780.1B |
| Ownersβ equity | β©955.4B | β©1.1T |
| Total equity | β©1.1T | β©1.2T |
Cash flow statement
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Operating cash flow | β©216.5B | β©193.5B |
| Investing cash flow | -β©183.5B | β©24.9B |
| Financing cash flow | -β©126.8B | -β©93.8B |
| Net change in cash | β | β |
| Cash at end of period | β©55.0B | β©192.3B |
Five-year trends
Key metrics
| Metric | Trend | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Revenue | β©1.1T | β©1.2T | β©1.3T | β©1.5T | β©1.5T | |
| Operating profit | β©49.0B | β©125.4B | β©158.1B | β©220.7B | β©216.2B | |
| Profit to owners | β©17.3B | β©81.5B | β©101.6B | β©165.4B | β©140.4B | |
| Total assets | β©1.9T | β©1.9T | β©1.9T | β©1.9T | β©2.0T | |
| Cash & equivalents | β©146.2B | β©209.2B | β©147.3B | β©55.0B | β©192.3B | |
| Ownersβ equity | β©831.9B | β©928.3B | β©1.0T | β©1.1T | β©1.2T |
How we read these numbers
From the notes
No material one-offs extracted from this filing.
Mixed
The numbers send mixed signals β dig into cash flow and leverage before drawing a conclusion.
On the income statement, revenue moved from β©1.5T to β©1.5T (β² +0.3%). Operating profit went from β to β (β).
Operating cash flow was β©193.5B (prior β©216.5B), with cash on the balance sheet at β©192.3B versus β©55.0B.
Liquidity & leverage
Short-term borrowings moved from β©336.1B to β©370.6B.
Capital buffer
Total equity moved from β©1.1T to β©1.2T.
Was this page helpful?
Source: DART 20250318001206
(νλ―Έμ½ν(μ£Ό)), period end 2024-12-31.